These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16627272)

  • 1. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.
    Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; Tubbs RR; Hsi ED
    Am J Clin Pathol; 2006 Apr; 125(4):625-33. PubMed ID: 16627272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system.
    Olsen RJ; Tang Z; Farkas DH; Bernard DW; Zu Y; Chang CC
    Arch Pathol Lab Med; 2006 Jul; 130(7):997-1003. PubMed ID: 16831057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.
    Lay M; Mariappan R; Gotlib J; Dietz L; Sebastian S; Schrijver I; Zehnder JL
    J Mol Diagn; 2006 Jul; 8(3):330-4. PubMed ID: 16825505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
    Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
    Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
    Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
    Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
    Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
    Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
    Lasho TL; Mesa R; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    McLornan D; Percy M; McMullin MF
    Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
    [No Abstract]   [Full Text] [Related]  

  • 20. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.